DOLACED® 250 mg

  • Product

    DOLACED 250 mg, coated tablets

  • Authorisation

    Unlicensed medicine

  • Active ingredient

    Diflunisal 250 mg

  • Indication

    ATTR-amyloidosis

  • Storage condition

    Below 25 °C

DOLACED is prescribed for ATTR-amyloidosis in patients who, for medical reasons, cannot be adequately treated with the licensed medicine Vyndaqel® (EU/1/11/717/001).

ATTR-amyloidosis is a hereditary form of amyloidosis (aggregation of misfolded proteins) caused by a mutation in the protein transthyretin (TTR) or a misfolding of non-mutated TTR that can occur at elderly age.

Legal status

DOLACED is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGZ) has given permission for the supply.

DOLACED is supplied “from-pharmacy-to-pharmacy” on named patient basis. An order signed by the pharmacist and a physician’s statement from the prescribing physician are required for each order.

Availability for (Hospital) Pharmacies

In the Netherlands, DOLACED is supplied by ACE Apotheek. More information for (hospital) pharmacies in the Netherlands can be found on the website of ACE Apotheek.

(Hospital) Pharmacies outside the Netherlands that would like to know more about the availability of this product are welcome to contact us via our contact form.